Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Metabolic and Muscle Function in Prediabetes
Abstract
The overall goal of the study is to expand our pilot clinical study and further evaluate the translation of our preclinical findings of NMN supplementation on metabolic health in rodents to clinical therapy in people. To this end, we will conduct a randomized placebo-controlled trial in men and women with prediabetes to assess the effect of NMN supplementation on key metabolic, mitochondrial and inflammation outcomes in collaboration with VA St. Louis Health Care System (VASTLHCS). We coordinated the implementation of the research protocol with Washington University (WU) and VASTLHCS; finalized the study protocol and informed consent form to be used at WU and VASTLHCS; obtained WU IRB approval (December 5, 2019), VASTLHCS IRB (March 17, 2020), and VASTLHCS RDC (April 24, 2020); had obtain obtained a WOC appointment at VASTLHCS for three WU study team members; and obtained DoD HRPO approval (September 19, 2020). The study is registered at Clinicaltrials.gov. We are actively recruiting study participants.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1115264
Entities
People
- Mihoko Yoshino
- Samuel Klein
Organizations
- Washington University in St. Louis